Sanofi(US:SNY) Ge Long Hui·2025-07-31 09:12Group 1 - Sanofi's stock dropped over 4% in pre-market trading, reaching $47.23, following the release of its Q2 earnings report [1] - The company reported Q2 sales of €9.994 billion, meeting expectations with a year-on-year growth of 6%, and a 10.1% increase at constant exchange rates [1] - Excluding one-time items, the operating profit for the quarter was €2.461 billion, which fell short of the expected €2.57 billion due to rising R&D costs and higher profit-sharing with partner Regeneron Pharmaceuticals [1] Group 2 - Driven by strong demand for its flagship anti-inflammatory drug Dupixent, vaccines, and new therapies, Sanofi raised its full-year sales guidance, now expecting high single-digit growth instead of mid to high single-digit growth at constant exchange rates [1] - The company confirmed its forecast for a low double-digit growth in net profit for the year, which includes all expenses related to newly acquired businesses [1]